Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity

Blood

Volumn 102, Issue 6, 2003, Pages 2138-2145

  Melani, Cecilia ^a   Chiodoni, Claudia ^b   Forni, Guido ^b   Colombo, Mario P ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD3 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HEMATOPOIESIS; IMMUNE RESPONSE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; ONCOGENE C ERB; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0141456030     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0190     Document Type: Article

References (43)

1. Kitamura H, Kodama F, Odagiri S, Nagahara N, Inoue T, Kanisawa M. Granulocytosis associated with malignant neoplasms: a clinicopathologic study and demonstration of colony-stimulating activity in tumor extracts. Hum Pathol. 1989;20: 878-885.
2. Estrov Z, Talpaz M, Mavligit G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995;98:551-558.
3. Sato T, Omura M, Saito J, et al. Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and interleukin-6. Thyroid. 2000;10: 1113-1118.
4. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423-1432.
5. Staszewski H. Hematological paraneoplastic syndromes. Semin Oncol. 1997;24:329-333.
6. Fu YX, Watson G, Jimenez JJ, Wang Y, Lopez DM. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res. 1990;50:227-234.
7. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166.
8. + progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin Exp Metastasis. 1999;17:881-888.
9. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103.
10. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappaB activation in hemopoietic progenitor-cells. J. Immunol. 1998;160:1224-1232,
11. Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langherans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol. 1998;161:4842-4851.
12. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162: 5728-5737.
13. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678-689.
14. + progenitor cells. Hum Immunol. 2001;62:332-341.
15. Forni G, Giovarelli M, Lanfrancone L, Varesio L. Suppressor macrophages in tumor-bearing mice: inconsistency between in vivo and in vitro findings? Int J Cancer. 1982;29:695-698.
16. + T cells. Blood. 2000;96:3838-3846.
17. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963-2970.
18. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol. 2000;165:779-785.
19. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol. 2000;164:2214-2220.
20. + myeloid cells. J Immunol. 2001;166:5398-5406.
21. + cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood. 2000;95:212-220.
22. + immature myeloid suppressor cells. Int Immunol. 2002;14: 1125-1134.
23. + cells. J Immunol. 1998;161:5313-5320.
24. Varesio L, Giovarelli M, Landolfo S, Forni G. Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor. Cancer Res. 1979;39:4983-4988.
25. + cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer. 1997;73:663-669.
26. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
27. Di Carlo E, Diodoro MG, Boggio K, et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest. 1999;79:1261-1269.
28. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat Her-2/ Neu p 185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol. 2000;165:5133-5142.
29. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001;9;1195-1205.
30. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice. J Exp Med. 1998;188:589-596.
31. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
32. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med. 1999;190:125-133.
33. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood. 1997;89:4337-4347.
34. Diodoro MG, Di Carlo E, Zappacosta R, et al. Salivary carcinoma in HER-2/neu transgenic male mice: an angiogenic switch is not required for tumor onset and progression. Int J Cancer. 2000;88:329-335.
35. van der Loo JC, Slieker WA, Ploemacher RE. Use of ER-MP12 as a positive marker for the isolation of murine long-term in vitro repopulating stem cells. Exp Hematol. 1995;23:1002-1010.
36. Ling V, Luxenberg D, Wang J, et al. Structural identification of the hematopoietic progenitor antigen ER-MP12 as the vascular endothelial adhesion molecule PECAM-1 (CD31). Eur J Immunol. 1997;27:509-514.
37. + cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood. 1998;91:1196-1205.
38. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in antitumor immune responses, II: dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol. 1996;170:111-119.
39. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996;32A:2451-2460.
40. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.
41. Broxmeyer HE, Cooper S, Li ZH, et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol. 1995;62:203-215.
42. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 2001;8:841-849.
43. Heissig, B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.